G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D
D2 receptor
GRK
phosphorylation
β-arrestin
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
20 10 2023
20 10 2023
Historique:
received:
26
09
2023
revised:
16
10
2023
accepted:
18
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The D2 dopamine receptor (D2R) signals through both G proteins and β-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. β-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, receptor phosphorylation is indispensable for β-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for β-arrestin recruitment to the D2R, and the role of GRKs in D2R-β-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine the extent to which β-arrestin recruitment to the D2R is GRK-dependent. Genetic elimination of all GRK expression decreased, but did not eliminate, agonist-stimulated β-arrestin recruitment to the D2R or its subsequent internalization. However, these processes were rescued upon the re-introduction of various GRK isoforms in the cells with GRK2/3 also enhancing dopamine potency. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, decreased β-arrestin recruitment and receptor internalization, highlighting the importance of this GRK subfamily for D2R-β-arrestin interactions. These results were recapitulated using a phosphorylation-deficient D2R mutant, emphasizing that GRKs can enhance β-arrestin recruitment and activation independently of receptor phosphorylation.
Identifiants
pubmed: 37892234
pii: biom13101552
doi: 10.3390/biom13101552
pmc: PMC10605370
pii:
doi:
Substances chimiques
Arrestins
0
beta-Arrestins
0
G-Protein-Coupled Receptor Kinases
EC 2.7.11.16
Protein Isoforms
0
Receptors, Dopamine
0
Receptors, G-Protein-Coupled
0
GRK2 protein, human
EC 2.7.11.15
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Intramural NIH HHS
ID : ZIA NS002263
Pays : United States
Références
Sci Rep. 2012;2:301
pubmed: 22393477
J Biol Chem. 2015 Apr 24;290(17):10775-90
pubmed: 25770216
Sci STKE. 2005 Nov 01;2005(308):cm10
pubmed: 16267056
Pharmacol Ther. 2012 Jan;133(1):40-69
pubmed: 21903131
Nat Protoc. 2010 Sep;5(10):1666-77
pubmed: 20885379
Int J Mol Sci. 2023 Apr 01;24(7):
pubmed: 37047571
J Biol Chem. 2009 Dec 4;284(49):34103-15
pubmed: 19815545
Trends Pharmacol Sci. 2012 Mar;33(3):154-64
pubmed: 22277298
Trends Pharmacol Sci. 1992 Feb;13(2):61-9
pubmed: 1561715
Sci Rep. 2021 Apr 15;11(1):8288
pubmed: 33859231
Neuron. 2003 Apr 24;38(2):291-303
pubmed: 12718862
Pharmacol Rev. 2023 Sep;75(5):854-884
pubmed: 37028945
J Biol Chem. 2018 Apr 20;293(16):6161-6171
pubmed: 29487132
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14139-14149
pubmed: 32503917
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3712-7
pubmed: 10097102
J Biol Chem. 2009 May 29;284(22):15038-51
pubmed: 19332542
J Biol Chem. 2007 Apr 6;282(14):10576-84
pubmed: 17283075
Nat Commun. 2022 Jan 27;13(1):540
pubmed: 35087057
Sci Rep. 2020 Oct 15;10(1):17395
pubmed: 33060647
Mol Cell. 2023 Jun 15;83(12):2091-2107.e7
pubmed: 37209686
Curr Opin Cell Biol. 2014 Apr;27:63-71
pubmed: 24680432
Cell Chem Biol. 2023 Apr 20;30(4):362-382.e8
pubmed: 37030291
Nature. 2018 May;557(7705):381-386
pubmed: 29720660
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Br J Pharmacol. 2010 Jun;160(4):821-32
pubmed: 20590581
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163118
Cell Mol Life Sci. 2019 Nov;76(22):4423-4446
pubmed: 31432234
Br J Pharmacol. 2013 Mar;168(6):1355-74
pubmed: 23082996
FASEB J. 2021 Nov;35(11):e22013
pubmed: 34699610
J Biol Chem. 2014 Nov 28;289(48):33663-75
pubmed: 25336643
Elife. 2015 Aug 26;4:
pubmed: 26308580
Nucleic Acids Res. 2018 Jan 4;46(D1):D440-D446
pubmed: 29155946
J Biol Chem. 1994 May 6;269(18):13084-7
pubmed: 8175732
J Biol Chem. 2000 Dec 8;275(49):38213-20
pubmed: 10982802
J Biol Chem. 2001 Oct 5;276(40):37409-14
pubmed: 11473130
Nature. 2016 Mar 31;531(7596):665-8
pubmed: 27007854
J Biol Chem. 2004 Dec 31;279(53):55744-53
pubmed: 15501822
ACS Chem Biol. 2015 Jan 16;10(1):246-56
pubmed: 24984143
Sci Signal. 2020 Feb 04;13(617):
pubmed: 32019899
Nature. 2018 May;557(7705):452-456
pubmed: 29720655
Front Pharmacol. 2019 Feb 19;10:125
pubmed: 30837883
Nat Commun. 2016 Jul 11;7:12178
pubmed: 27397672
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Synapse. 2009 Jul;63(7):621-4
pubmed: 19309759
Mol Pharmacol. 2011 Aug;80(2):294-303
pubmed: 21596927
Nat Commun. 2022 Sep 26;13(1):5638
pubmed: 36163356
Int J Mol Sci. 2023 Apr 04;24(7):
pubmed: 37047716
Pharmacol Res. 2016 Sep;111:1-16
pubmed: 27178731
Cells. 2021 Mar 04;10(3):
pubmed: 33806476
Curr Opin Struct Biol. 2022 Aug;75:102406
pubmed: 35738165
Mol Endocrinol. 2010 Mar;24(3):574-86
pubmed: 20160122
J Biol Chem. 2004 Nov 19;279(47):49533-41
pubmed: 15347675
Mol Cell Endocrinol. 2019 Mar 15;484:34-41
pubmed: 30703488